Antimicrobial Platform San Diego based biotech with a proprietary SLAY platform for rapid identification of novel antibiotic scaffolds targeting Gram-negative pathogens, presenting a potential partnership angle for collaborative research and contract screening services.

Early Stage Revenue Current revenue is minimal, indicating a potential need for grant funding, strategic partnerships, or milestone-based collaborations to fund R&D and scale platform capabilities.

Security Critical Market Addressing antimicrobial resistance, a high-priority global health issue, which can attract government grants, defense and public health sector interest, and enterprise clients seeking innovative solutions.

Targeted Outreach Small team size (2-10 employees) suggests a lean operation; scalable partnerships should emphasize quick pilots, white-label screening, and joint development agreements to minimize onboarding friction.

Tech Versatility Technology stack includes Python, Django, and web tools, which may enable SaaS or software-assisted collaboration models for data sharing, screening workflows, and custom library design services.